STAT - Reporting from the frontiers of health and medicine

Health

By Leah Samuel

Biotech

By STAT staff

Politics

Pharmalot New proposal looks to involve every local U.S. government in opioid settlements
Biotech CRISPR lab begs the question: Where is the line between industry and academia?
Biotech Pfizer spends $11.4 billion to buy Array BioPharma for its cancer drug chemistry
First Opinion As global markets for generic drugs fail, poor people pay the price
Politics Facing progressive pressure, Pelosi could expand her drug pricing plan to negotiate prices for $118 billion worth of medicines

Exclusive analysis of biotech, pharma, and the life sciences

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger
FDA warns of one patient death from a fecal transplant
Pharmalittle: Pfizer to buy Array for $11 billion, Teva settlement in Oklahoma may hit a new snag

Exclusive

Health

Health

Politics

Special Report

In the Lab

Health Medical schools are starting to diversify. But they’re learning hard lessons along the way
First Opinion Ghost networks of psychiatrists make money for insurance companies but hinder patients’ access to care
Biotech Pfizer spends $11.4 billion to buy Array BioPharma for its cancer drug chemistry
Health ‘They have to get the shots’: Trump, once a vaccine skeptic, changes his tune amid measles outbreaks
Politics Amgen, Merck, and Eli Lilly sue over Trump administration policy to require drug prices in TV ads